Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 1/2 2Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 2Exocrine Pancreatic Insufficiency 1

Interventions

pembrolizumab 409Cyclophosphamide 398Carboplatin 307Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 209Bevacizumab 207fludarabine 195Docetaxel 186Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 121Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Pancrelipase × Clear all
NCT05642962 2026-02-25

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
17 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02985801 2021-03-15

PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer

Mayo Clinic

Phase 1/2 Terminated
16 enrolled 5 charts
Gastrointestinal

Exocrine Pancreatic Insufficiency, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡